Cantor Fitzgerald Reiterates Overweight Rating on Janux Therapeutics (JANX)
Tweet Send to a Friend
Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $200.00 price target on Janux Therapeutics (NASDAQ: JANX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
